Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 55.59 -0.95 (-1.68%) Market Cap: 3.47 Bil Enterprise Value: 3.14 Bil PE Ratio: 0 PB Ratio: 308.96 GF Score: 58/100

Rhythm Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 12:45PM GMT
Release Date Price: $13 (+1.25%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

Good morning. I'd like to welcome you to the 19th Annual Morgan Stanley Healthcare Conference. Before I get started, let me get to the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I am happy to have with me today this morning, for our opening session -- my opening session, from Rhythm Pharmaceuticals, Chairman, CEO and President, David Meeker. Let's get started. I guess to start off here, if you could briefly walk us through Rhythm Pharmaceuticals from a top level, what is the company's overall mission?

David P. Meeker
Rhythm Pharmaceuticals, Inc. - Chairman, President & CEO

Thank you, David. Appreciate being on. So we are focused on rare genetic diseases of obesity. And we know that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot